Senate passes bill removing administrative barriers to opioid treatment

The Senate approved legislation to eliminate administrative hurdles for opioid use disorder treatment, including prior authorization requirements for medication-assisted treatment (MAT). The bill specifically targets Medicaid and state-regulated health plans, mandating coverage for FDA-approved MAT drugs without preauthorization. For practices providing addiction medicine, this reduces billing friction for buprenorphine and naltrexone prescriptions starting with the 2027 plan year. The legislation mirrors similar provisions in the SUPPORT Act but extends them to all state Medicaid programs. Billing teams should prepare for smoother claims submission for MAT services after the effective date, though verification of state-level implementation remains necessary.